1. Home
  2. DAWN vs FAX Comparison

DAWN vs FAX Comparison

Compare DAWN & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • FAX
  • Stock Information
  • Founded
  • DAWN 2018
  • FAX 1986
  • Country
  • DAWN United States
  • FAX United States
  • Employees
  • DAWN N/A
  • FAX N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • FAX Investment Managers
  • Sector
  • DAWN Health Care
  • FAX Finance
  • Exchange
  • DAWN Nasdaq
  • FAX Nasdaq
  • Market Cap
  • DAWN 658.9M
  • FAX 658.9M
  • IPO Year
  • DAWN 2021
  • FAX N/A
  • Fundamental
  • Price
  • DAWN $6.71
  • FAX $16.10
  • Analyst Decision
  • DAWN Strong Buy
  • FAX
  • Analyst Count
  • DAWN 6
  • FAX 0
  • Target Price
  • DAWN $30.17
  • FAX N/A
  • AVG Volume (30 Days)
  • DAWN 1.3M
  • FAX 833.6K
  • Earning Date
  • DAWN 08-05-2025
  • FAX 01-01-0001
  • Dividend Yield
  • DAWN N/A
  • FAX 12.09%
  • EPS Growth
  • DAWN N/A
  • FAX N/A
  • EPS
  • DAWN N/A
  • FAX N/A
  • Revenue
  • DAWN $161,922,000.00
  • FAX N/A
  • Revenue This Year
  • DAWN $17.98
  • FAX N/A
  • Revenue Next Year
  • DAWN $49.50
  • FAX N/A
  • P/E Ratio
  • DAWN N/A
  • FAX N/A
  • Revenue Growth
  • DAWN N/A
  • FAX N/A
  • 52 Week Low
  • DAWN $6.08
  • FAX $2.33
  • 52 Week High
  • DAWN $16.76
  • FAX $2.84
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 47.98
  • FAX 55.47
  • Support Level
  • DAWN $6.32
  • FAX $15.84
  • Resistance Level
  • DAWN $7.18
  • FAX $16.10
  • Average True Range (ATR)
  • DAWN 0.29
  • FAX 0.14
  • MACD
  • DAWN 0.01
  • FAX 0.00
  • Stochastic Oscillator
  • DAWN 36.11
  • FAX 69.25

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

Share on Social Networks: